Corporate Information

Board of Directors

Kyle A. Lefkoff
Chairman, Array BioPharma Inc. Board of Directors; and General Partner, Boulder Ventures, Ltd.
Audit Committee
Compensation Committee
Gwen A. Fyfe, M.D.
Independent Consultant & Former Vice President, Oncology Development,
Genentech, Inc.

Compensation Committee
Corporate Governance Committee
Clinical Development Committee
Charles M. Baum, M.D., Ph.D.
President and Chief Executive Officer,
Mirati Therapeutics

Audit Committee
Clinical Development Committee
John A. Orwin
Former Chief Executive Officer (Relypsa, Inc.)
Compensation Committee
Corporate Governance Committee
Clinical Development Committee
Ron Squarer
Chief Executive Officer, Array BioPharma Inc.
Shalini Sharp
Chief Financial Officer and Executive Vice President, Ultragenyx Pharmaceutical Inc.
Audit Committee
Gil J. Van Lunsen
Former Managing Partner, KPMG LLP
Audit Committee
Corporate Governance Committee

Executive Officers

Ron Squarer
Chief Executive Officer
Jason Haddock
Chief Financial Officer
Curtis Oltmans
Executive Vice President,
General Counsel and Secretary
Andrew Robbins
Chief Operating Officer
Nicholas A. Saccomano, Ph.D.
Chief Scientific Officer
Victor Sandor, M.D.
Chief Medical Officer

Stakeholder Information

Outside Legal Counsel
Ballard Spahr LLP
Boulder, Colorado
Independent Auditors
Denver, Colorado
Corporate Headquarters
Array BioPharma Inc.
3200 Walnut Street
Boulder, Colorado 80301
Transfer Agent and Registrar
Communications concerning stock transfer requirements, lost certificates and changes of address should be directed to the Transfer Agent:
American Stock Transfer and Trust Company
6201 15th Avenue
Brooklyn, NY 11219
Annual Meeting
October 26, 2017
1:00 pm MDT
Hyatt Place Boulder/Pearl Street
2280 Junction Place
Boulder, Colorado 80301
Stockholder Inquiries
Inquiries from stockholders and potential investors regarding our company are always welcome and will receive a prompt response. Please direct your requests for information to:
Investor Relations
Array BioPharma Inc.
3200 Walnut Street
Boulder, Colorado 80301
Information regarding Array BioPharma is also available at:
Stock Listing
Array BioPharma common stock is traded on the Nasdaq Stock Market under the symbol ARRY.


This Annual Report and other documents we file with the Securities and Exchange Commission, or SEC, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties. In addition, we may make forward-looking statements in our press releases or in other oral or written communications with the public. These forward-looking statements include, but are not limited to, statements concerning the future drug development plans and projected timelines for the initiation and completion of preclinical and clinical trials by Array or our partners; the potential for the results of ongoing preclinical or clinical trials conducted by Array or our partners to support regulatory approval or the marketing success of drug candidates; our plans with respect to the timing and scope of the expansion of our clinical and commercialization capabilities; other statements regarding our future product development and regulatory strategies, including with respect to specific indications; the ability of third-party contract manufacturing parties to support our drug development activities; any statements regarding our future financial performance, results of operations or sufficiency of capital resources to fund our operating requirements; and any other statements that are other than statements of historical fact.

Although we believe the assumptions upon which our forward-looking statements are based currently to be reasonable, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially-viable drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; risks associated with our dependence on our partners for the clinical development and commercialization of our out-licensed drug candidates; the ability of our partners and of Array to meet objectives tied to milestones and royalties; our ability to attract and retain experienced scientists and management; our ability to achieve and maintain profitability; and the risk factors set forth under the caption "Item 1A. Risk Factors" in the Fiscal 2017 Annual Report on Form 10-K. We are providing this information as of the date of this report. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

Market and Industry Data

Unless otherwise indicated, information contained in this annual report or contained in or incorporated by reference in the Fiscal 2017 Annual Report on Form 10-K concerning the cancer market, the drug market and our other markets, including our general expectations and market position, market opportunity and market share, is based on information from independent industry analysts and third-party sources and management estimates. Management estimates are derived from publicly-available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and markets, which we believe to be reasonable.

We have not independently verified or verified with any independent source any third-party information and cannot assure you of its accuracy or completeness. In addition, while we believe the market position, market opportunity and market share information included in this Annual Report is generally reliable, such information is inherently imprecise. Such data involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading "Item 1A. Risk Factors" in the Fiscal 2017 Annual Report on Form 10-K.